AstraZeneca

SERENA 2 | D8530C00002

NCT04214288

JCP079

A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer (SERENA-2)

Status:

Recruiting

26459-200.png

II

Phase

Line of Therapy.png

2nd

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

ER+, HER2-

Investigational

Product

AZD9833

Selective degrader of the estrogen receptor (SERD) (p.o.)

Treatment Arms

o Experimental: AZD9833 Dose A

o Experimental: AZD9833 Dose B

o Experimental: AZD9833 Dose C

o Active Comparator: Fulvestrant 500 mg